Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Levetiracetam
Keppra
Routinely available
SMC (397/07)
29/03/2023
Indication
Monotherapy for epilepsy
Therapeutic Area
Central nervous system
Status Description
Routinely available
Formulation
250mg, 500mg, 750mg, 1000mg tablets and oral solution 100mg/ml
Comments
-
Link to Advice
Advice Published
11/02/2008
SMC Submission Type
Resubmission
SMC Status
Restricted